dehydroepiandrosterone has been researched along with Pruritus in 2 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Pruritus: An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cholic and chenodeoxycholic acids were determined in 42 cord plasma samples after pregnancies complicated by maternal intrahepatic cholestasis and in 20 cord plasma samples after uncomplicated pregnancies with a gas-chromatographic method." | 3.65 | Fetal bile acid levels in pregnancies complicated by maternal intrahepatic cholestasis. ( Laatikainen, TJ, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Labrie, F | 1 |
| Archer, DF | 1 |
| Bouchard, C | 1 |
| Girard, G | 1 |
| Ayotte, N | 1 |
| Gallagher, JC | 1 |
| Cusan, L | 1 |
| Baron, M | 1 |
| Blouin, F | 1 |
| Waldbaum, AS | 1 |
| Koltun, W | 1 |
| Portman, DJ | 1 |
| Côté, I | 1 |
| Lavoie, L | 1 |
| Beauregard, A | 1 |
| Labrie, C | 1 |
| Martel, C | 1 |
| Balser, J | 1 |
| Moyneur, É | 1 |
| Laatikainen, TJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| DHEA Against Vaginal Atrophy - Safety Study of 12 Months[NCT01256671] | Phase 3 | 530 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Trial on the Preventive Effect of Intravaginal Prasterone (DHEA, Intrarosa®) on Recurrent Urinary Tract Infections in Women With Genitourinary Syndrome of Menopause[NCT03854396] | Phase 3 | 0 participants (Actual) | Interventional | 2020-05-31 | Withdrawn (stopped due to due to termination of ISR by PI with agreement by grant sponsor) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The severity of dyspareunia was evaluated by a questionnaire. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline: Subgroup MS | Week 52: Subgroup MS | Change from Baseline: Subgroup MS | Baseline: Subgroup MBS/MS | Week 52: Subgroup MBS/MS | Change from Baseline: Subgroup MBS/MS | |
| 0.50% DHEA | 2.53 | 0.85 | -1.68 | 2.57 | 0.87 | -1.69 |
The severity of irritation/itching was evaluated by a questionnaire. The severity of irritation/itching recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline: Subgroup MS | Week 52: Subgroup MS | Change from Baseline: Subgroup MS | Baseline: Subgroup MBS/MS | Week 52: Subgroup MBS/MS | Change from Baseline: Subgroup MBS/MS | |
| 0.50% DHEA | 2.10 | 0.60 | -1.50 | 2.13 | 0.74 | -1.39 |
The severity of vaginal dryness was evaluated by a questionnaire. The severity of vaginal dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline: Subgroup MS | Week 52: Subgroup MS | Change from Baseline: Subgroup MS | Baseline: Subgroup MBS/MS | Week 52: Subgroup MBS/MS | Change from Baseline: Subgroup MBS/MS | |
| 0.50% DHEA | 2.22 | 0.59 | -1.63 | 2.19 | 0.67 | -1.52 |
The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | percentage of parabasal cells (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline: Subgroup ALL | Week 52: Subgroup ALL | Change from Baseline: Subgroup ALL | Baseline: Subgroup VVA | Week 52: Subgroup VVA | Change from Baseline: Subgroup VVA | |
| 0.50% DHEA | 55.49 | 12.81 | -42.67 | 63.95 | 14.80 | -49.14 |
The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | percentage of superficial cells (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline: Subgroup ALL | Week 52: Subgroup ALL | Change from Baseline: Subgroup ALL | Baseline: Subgroup VVA | Week 52: Subgroup VVA | Change from Baseline: Subgroup VVA | |
| 0.50% DHEA | 2.02 | 9.42 | 7.41 | 0.96 | 8.81 | 7.85 |
A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | pH (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline: Subgroup ALL | Week 52: Subgroup ALL | Change from Baseline: Subgroup ALL | Baseline: Subgroup VVA | Week 52: Subgroup VVA | Change from Baseline: Subgroup VVA | |
| 0.50% DHEA | 6.23 | 5.09 | -1.14 | 6.40 | 5.13 | -1.27 |
The long-term safety of intravaginal prasterone has been evaluated on different parameters including the endometrium. For this purpose, endometrial biopsies were performed at screening and at the end of the study (52 weeks) or at discontinuation visit for women who were exposed to intravaginal DHEA (prasterone) for at least 12 weeks. At screening, the endometrium had to be atrophic/inactive for women to be enrolled in the study. Only the end-of-study data are presented. (NCT01256671)
Timeframe: Baseline and Week 52 (or discontinuation)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Endometrium: Atrophic/Inactive | Endometrium: No/Insufficient Tissue for Diagnosis | |
| 0.50% DHEA | 421 | 36 |
The long-term safety of intravaginal prasterone has been evaluated on different parameters including the serum levels of DHEA and its metabolites. For this purpose, blood samples were collected at Baseline and different post-Baseline timepoints for the determination of serum steroid levels by a central laboratory using validated liquid chromatography tandem mass spectrometry (LC-MS/MS) methods. The serum levels of dehydroepiandrosterone (DHEA), estradiol (E2) and testosterone (TESTO) obtained at Baseline and Week 52 as well as the change from Baseline to Week 52 are presented. (NCT01256671)
Timeframe: Baseline and Week 52
| Intervention | pg/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| DHEA: Baseline | DHEA: Week 52 | DHEA: Change from Baseline | E2: Baseline | E2: Week 52 | E2: Change from Baseline | TESTO: Baseline | TESTO: Week 52 | TESTO: Change from Baseline | |
| 0.50% DHEA | 2071.61 | 2997.25 | 925.65 | 6.05 | 4.46 | -1.59 | 161.28 | 189.44 | 28.17 |
1 trial available for dehydroepiandrosterone and Pruritus
| Article | Year |
|---|---|
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys | 2015 |
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys | 2015 |
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys | 2015 |
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Topics: Administration, Intravaginal; Adult; Aged; Atrophy; Dehydroepiandrosterone; Double-Blind Method; Dys | 2015 |
1 other study available for dehydroepiandrosterone and Pruritus
| Article | Year |
|---|---|
Fetal bile acid levels in pregnancies complicated by maternal intrahepatic cholestasis.
Topics: Androstenols; Apgar Score; Birth Weight; Chenodeoxycholic Acid; Cholestasis; Cholic Acids; Chromatog | 1975 |